ORIGINAL RESEARCH article
Front. Toxicol.
Sec. Regulatory Toxicology
Volume 7 - 2025 | doi: 10.3389/ftox.2025.1657189
This article is part of the Research TopicNew Approach Methodologies in Regulatory ToxicologyView all articles
Error-Corrected Next Generation Sequencing Mutagenicity Assays in Human HepaRG™ Cells as Human-Relevant Genetic Toxicology New Approach Methodology
Provisionally accepted
- 1ScitoVation, Research Triangle Park, United States
- 2ScitoVation LLC, Research Triangle Park, United States
Select one of your emails
You have multiple emails registered with Frontiers:
Notify me on publication
Please enter your email address:
If you already have an account, please login
You don't have a Frontiers account ? You can register here
Human metabolically competent HepaRG™ (HepaRG) cells have been developed as a humanrelevant New Approach Methodology (NAM) in genetic toxicology, serving as a non-animal alternative to rodent-based mutagenicity testing following a positive Ames test. Error-corrected next-generation sequencing (ecNGS) offers a promising approach for improving sensitivity, specificity, and mechanistic insight in genotoxicity and mutagenicity testing. We applied duplex sequencing to quantify chemically induced point mutations in metabolically competent human HepaRG cells following exposure to a diverse panel of genotoxic agents, including ethyl methanesulfonate (EMS), N-ethyl-N-nitrosourea (ENU), benzo[a]pyrene (BAP), cisplatin, cyclophosphamide, and etoposide. Duplex sequencing detected dose-responsive increases in mutation frequency for ENU and EMS, with distinct substitution patterns consistent with alkylating mechanisms. BAP and cisplatin induced modest increases in mutation frequency and C>A-enriched spectra, while cyclophosphamide yielded minimal mutagenicity under the conditions tested. Etoposide triggered strong cytogenetic responses but did not increase point mutations, consistent with its clastogenic mode of action. COSMIC mutational signature analysis revealed modest enrichment of SBS4 (BAP), SBS11 (EMS), and SBS31/32 (cisplatin), supporting the mechanistic relevance of the model. These results demonstrate the reproducibility and specificity of ecNGS for detecting low-frequency point mutations and characterizing mutational mechanisms. When combined with complementary cytogenetic assays, duplex sequencing enables a more complete and human-relevant evaluation of genotoxic potential. Our findings support the integration of ecNGS into next-generation genotoxicity testing strategies as a New Approach Methodology for regulatory decision-making.
Keywords: NAM, Mutagenecity, Duplex-seq, ecNGS, HepaRG
Received: 01 Jul 2025; Accepted: 07 Aug 2025.
Copyright: © 2025 Barutcu, Bhattarai, Samuel, Scaglione and Recio. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) or licensor are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.
* Correspondence: Leslie Recio, ScitoVation LLC, Research Triangle Park, United States
Disclaimer: All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article or claim that may be made by its manufacturer is not guaranteed or endorsed by the publisher.